# Carcinoid Syndrome

Carcinoid syndrome requires biochemical confirmation, staging of the underlying well-differentiated neuroendocrine tumor, prompt control of hormone-mediated symptoms, and structured surveillance for carcinoid heart disease. Refractory diarrhea should trigger assessment of tumor burden, somatostatin analog delivery, and serotonin-directed or tumor-directed therapy.

**Clinical question:** How should clinicians confirm, stage, treat, and monitor carcinoid syndrome and its cardiac and perioperative complications?

Updated: 2026-08-24T17:21:14.645304+00:00

## What matters in practice
- In a compatible syndrome, obtain urinary 5-hydroxyindoleacetic acid (5-HIAA) to support serotonin-secreting neuroendocrine tumor activity, then use imaging to localize and stage disease. [16]
- Long-acting octreotide or lanreotide is first-line antisecretory therapy; octreotide LAR is administered every 4 weeks intramuscularly and lanreotide every 4 weeks by deep subcutaneous injection. [12]
- Persistent diarrhea despite somatostatin analog therapy warrants assessment for disease progression and consideration of telotristat, somatostatin analog dose-interval escalation, liver-directed therapy, or PRRT when clinically appropriate. [8][12][15][20]
- Patients with carcinoid syndrome undergoing surgery should have preoperative transthoracic echocardiography and perioperative planning for carcinoid crisis, particularly when liver metastases or cardiac disease are present. [18][19][23]
- Advanced small-intestinal neuroendocrine tumors with carcinoid syndrome carry substantial carcinoid heart disease risk, reported in up to 50% of affected patients. [9]

## Identify crisis physiology and occult carcinoid heart disease

Stabilize hemodynamics first, then determine whether symptoms reflect hormone excess, cardiac involvement, or treatment-related progression.

Treat abrupt flushing, bronchospasm, severe diarrhea, or hemodynamic instability during tumor manipulation, anesthesia, or other physiologic stress as possible carcinoid crisis. Crisis is more likely in patients with liver metastases and can be life-threatening. [23] Coordinate urgent anesthesia, oncology, and surgical management; intravenous octreotide has been used intraoperatively for hypotensive crisis, including 500 to 1,000 mcg boluses repeated at 5-minute intervals until symptom control in a pediatric drug monograph. [22]

Assess for carcinoid heart disease at presentation of clinically established carcinoid syndrome and before operative interventions. Obtain transthoracic echocardiography to identify valvular dysfunction or heart failure; this is specifically recommended preoperatively when carcinoid syndrome is present. [18][19] Escalate promptly to a multidisciplinary heart-valve and neuroendocrine tumor team when echocardiography identifies clinically consequential valvular disease, because valve replacement may be complicated by persistent hormonal activity, hepatic dysfunction, and right-sided heart failure. [24]

Do not attribute edema, ascites, fatigue, or exertional limitation solely to hepatic tumor burden or diarrhea-related volume loss. In advanced small-intestinal neuroendocrine tumors with carcinoid syndrome, carcinoid heart disease develops in up to 50% of patients. [9]
- Before elective abdominal, hepatic, or cardiac surgery: document carcinoid syndrome status, obtain transthoracic echocardiography when syndrome is identified, and formulate perioperative somatostatin analog and hemodynamic plans. [18][19]
- When valve surgery is being considered: assess current hormonal control and hepatic and right-heart status because each can complicate perioperative management. [24]

*High-consequence presentations requiring immediate reassessment. [18][19][23][24]*

| Presentation | Immediate action | Decision consequence |
| --- | --- | --- |
| Hemodynamic instability, bronchospasm, flushing, or severe diarrhea around anesthesia or tumor manipulation [23] | Treat as possible carcinoid crisis; involve anesthesia and procedural teams and use an intravenous octreotide-based rescue plan. [22][23] | Do not proceed with routine procedural management without crisis preparedness. [23] |
| Carcinoid syndrome before planned surgery [18][19] | Obtain transthoracic echocardiography for valvular dysfunction and heart failure. [18][19] | Cardiac findings may alter operative sequencing, anesthetic planning, and valve-team involvement. [19][24] |
| Right-sided heart failure or valvular dysfunction [16][24] | Refer for multidisciplinary assessment of carcinoid heart disease and valve intervention candidacy. [24] | Persistent hormonal activity, liver dysfunction, and right-heart failure increase procedural complexity. [24] |

## Confirm serotonin excess and define the tumor phenotype driving treatment

Biochemical confirmation and tumor characterization determine whether management should prioritize antisecretory control, cytoreduction, or systemic tumor therapy.

In patients with a compatible pattern of recurrent flushing, secretory diarrhea, bronchospasm, or suspected hormone-mediated right-sided valvular disease, measure urinary 5-HIAA as the principal biochemical test for carcinoid syndrome. Urinary 5-HIAA testing supports the diagnosis, while imaging is used to localize and stage the underlying neuroendocrine tumor. [16]

Interpret a positive biochemical and clinical syndrome in the context of tumor distribution. Carcinoid syndrome is most commonly associated with metastatic, well-differentiated midgut neuroendocrine tumors, especially when liver metastases allow serotonin and other tumor mediators to reach the systemic circulation. [10][16] Small-intestinal neuroendocrine tumors frequently metastasize to the liver, and approximately 30% may present with carcinoid syndrome. [7]

Establish whether the malignancy is a well-differentiated gastrointestinal neuroendocrine tumor or a poorly differentiated high-grade neuroendocrine carcinoma. This distinction changes systemic treatment direction: somatostatin analog–based approaches are central for functioning well-differentiated disease, whereas platinum-etoposide chemotherapy is described as the mainstay for high-grade or metastatic neuroendocrine carcinomas. [14] Pathology review is therefore necessary whenever morphology, grade, clinical tempo, or treatment response raises concern for high-grade disease.
- Order urinary 5-HIAA when symptoms suggest serotonin-mediated carcinoid syndrome; use imaging after biochemical evaluation to identify primary site, liver metastases, and overall extent. [16]
- Review pathology and disease tempo before selecting a well-differentiated NET pathway versus a poorly differentiated NEC chemotherapy pathway. [14]
- In known NET with new diarrhea or flushing, reassess tumor distribution and biochemical activity rather than assuming loss of somatostatin analog effect. [12][16]

### Clinical pattern that changes the next test

A syndrome arising in a patient with known small-intestinal NET and liver metastases strongly supports tumor-mediated serotonin excess and warrants urinary 5-HIAA assessment plus restaging imaging. [7][10][16] Conversely, a rapidly progressive malignancy or pathology suggestive of poorly differentiated NEC should shift the systemic-treatment discussion toward platinum-etoposide–based treatment rather than treating symptoms alone. [14]

*Actionable tumor-pattern distinctions in suspected carcinoid syndrome. [7][10][14][16]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Compatible symptoms plus elevated urinary 5-HIAA [16] | Supports serotonin-secreting carcinoid syndrome. [16] | Stage and localize the neuroendocrine tumor with imaging. [16] |
| Small-intestinal NET with liver metastases [7][10] | Common clinical setting for systemic hormone exposure and carcinoid syndrome. [7][10] | Prioritize antisecretory therapy, cardiac assessment, and tumor-burden strategy. [12][16] |
| Poorly differentiated high-grade neuroendocrine carcinoma [14] | Biology and systemic therapy differ from well-differentiated NET. [14] | Use a high-grade NEC treatment pathway; platinum-etoposide chemotherapy is the described mainstay. [14] |

## Start somatostatin analog therapy and separate symptom control from tumor control

Antisecretory therapy is the initial medical backbone for functional well-differentiated disease.

Initiate a long-acting somatostatin analog for symptomatic carcinoid syndrome. Available long-acting agents are octreotide LAR, given intramuscularly every 4 weeks, and lanreotide, given by deep subcutaneous injection every 4 weeks. Both have antisecretory and antiproliferative evidence in midgut neuroendocrine tumors and similar somatostatin receptor subtype-binding profiles, particularly affinity for SSTR2. [12]

For initial or nonrefractory carcinoid syndrome, consensus guidance lists octreotide LAR 20 to 30 mg intramuscularly as an available U.S. option; immediate-release octreotide can be used for breakthrough symptoms. [15] The treatment target is reduction of flushing and diarrhea while the oncology team concurrently evaluates disease burden and radiographic trajectory.

Continue somatostatin analog therapy in functioning carcinoid syndrome when additional tumor-directed therapy is introduced. Long-term therapy is described as lifelong for carcinoid syndrome and other responsive functioning syndromes, including after radiologic or clinical progression, although continuation after progression in nonfunctioning gastrointestinal NET remains controversial. [13] This distinction matters: persistent hormone secretion remains a clinical indication for ongoing antisecretory treatment even when a second-line antitumor therapy is added. [13]
- Use octreotide LAR 20 to 30 mg IM for initial/nonrefractory syndrome when selecting the regimen specified in consensus guidance. [15]
- Use immediate-release octreotide for breakthrough symptoms. [15]
- Record flushing frequency, bowel-movement burden, breakthrough symptom timing, and urinary 5-HIAA trend to determine whether apparent treatment failure is symptomatic, biochemical, radiographic, or mixed. [16][20]

*Medical treatment sequence for hormone-mediated symptoms. [12][13][15][20]*

| Clinical state | Treatment action | Key limitation or follow-up |
| --- | --- | --- |
| Initial symptomatic carcinoid syndrome [15] | Start a long-acting somatostatin analog; octreotide LAR 20-30 mg IM is a listed U.S. option. [15] | Use immediate-release octreotide for breakthrough symptoms. [15] |
| Functioning syndrome receiving subsequent antitumor therapy [13] | Continue somatostatin analog therapy for ongoing hormone control. [13] | The evidence controversy over continuation after progression applies principally to nonfunctioning gastrointestinal NET. [13] |
| Diarrhea despite somatostatin analog therapy [12][20] | Assess adherence, injection timing, tumor burden, and biochemical activity; consider escalation or telotristat-based management. [15][20] | Choose tumor-directed treatment if symptom failure parallels progressive tumor burden. [8][12] |

## Treat refractory diarrhea by identifying the dominant failure mechanism

Persistent symptoms on a somatostatin analog should prompt simultaneous assessment of hormone excess and liver-dominant tumor burden.

For refractory carcinoid syndrome with stable tumor volume, consensus guidance supports antidiarrheal agents and recommends considering dose escalation or shortening the dosing interval of the long-acting somatostatin analog; however, prospective randomized evidence for somatostatin analog dose or interval escalation is lacking. [15] A symptom pattern that worsens near the end of the dosing cycle favors an administration-interval strategy, whereas worsening symptoms with radiographic progression favors tumor-directed escalation.

Add telotristat ethyl for persistent carcinoid-syndrome diarrhea in patients already receiving somatostatin analog therapy. In placebo-controlled phase 3 studies, telotristat 250 mg three times daily reduced urinary 5-HIAA, and PRRT with 177Lu-DOTATATE has also reduced diarrhea and flushing in carcinoid syndrome. [8][20] Telotristat should be taken with food; the cited product information advises reducing to 250 mg twice daily as tolerated in Child-Pugh A impairment, 250 mg once daily as tolerated in Child-Pugh B impairment, and avoiding use in Child-Pugh C impairment. [20]

When liver metastases are unresectable and symptom control remains suboptimal on somatostatin analog therapy, hepatic arterial embolization is an appropriate palliative option by NANETS consensus and is associated with high rates of symptom improvement in reported series of hormonal syndromes. [12] In the same clinical setting, systemic options such as PRRT or everolimus may be added to somatostatin analogs, but comparative evidence for symptom control across these approaches remains limited. [12]

For somatostatin receptor-positive advanced NET with persistent tumor growth or hormone-related symptoms, PRRT is a tumor-directed option; 177Lu-DOTATATE has demonstrated reduction in flushing and diarrhea in patients with carcinoid syndrome. [6][8] Select the modality with the multidisciplinary NET team according to somatostatin receptor status, extent and distribution of disease, liver-directed therapy feasibility, prior treatments, and cardiac reserve.
- Stable tumor volume with ongoing diarrhea: optimize symptom-directed therapy, including antidiarrheals, somatostatin analog dose-interval modification, and telotristat. [15][20]
- Progressive or liver-dominant disease with uncontrolled hormonal symptoms: consider hepatic arterial embolization, PRRT, or systemic therapy in a NET-directed multidisciplinary plan. [8][12]
- Avoid telotristat in severe hepatic impairment (Child-Pugh C); use reduced dosing as tolerated in Child-Pugh A or B impairment. [20]

### Role of chemotherapy

Do not default to cytotoxic chemotherapy for a well-differentiated gastrointestinal NET solely because carcinoid symptoms are difficult to control. Phase III data supporting chemotherapy in gastrointestinal NET are lacking, and ENETS 2016 and NANETS 2017 guidance did not support routine chemotherapy for this setting. [13] Selected high-grade grade 2 gastrointestinal NETs have been treated with FOLFOX or capecitabine-temozolomide in later lines in some guidance, whereas poorly differentiated NEC follows a different platinum-etoposide–based paradigm. [13][14]

*Escalation choices for somatostatin analog–refractory carcinoid syndrome. [8][12][15][20]*

| Predominant problem | Preferred next step | Important qualifier |
| --- | --- | --- |
| Persistent diarrhea with stable tumor volume [15] | Use antidiarrheals; consider higher somatostatin analog dose or shorter interval; add telotristat when appropriate. [15][20] | Somatostatin analog escalation lacks prospective randomized evidence. [15] |
| Persistent diarrhea on somatostatin analog therapy [20] | Telotristat ethyl 250 mg orally three times daily with food. [20] | Reduce as tolerated in Child-Pugh A or B impairment; do not use in Child-Pugh C impairment. [20] |
| Unresectable liver metastases with suboptimal hormonal control [12] | Consider hepatic arterial embolization for palliation. [12] | Systemic PRRT or everolimus may be alternatives or additions; comparative symptom-control data are limited. [12] |
| Advanced somatostatin receptor-positive NET with persistent symptoms or growth [6][8] | Consider PRRT with 177Lu-DOTATATE. [6][8] | PRRT has reduced diarrhea and flushing in carcinoid syndrome. [8] |

## Monitor hormone activity, tumor trajectory, and cardiac progression in parallel

Clinical symptom control does not replace biochemical, imaging, or cardiac reassessment.

At each treatment review, document bowel-movement burden, flushing frequency, breakthrough symptoms, somatostatin analog injection timing, and adverse effects. Use urinary 5-HIAA as a biochemical marker of serotonin activity and repeat imaging to assess localization, staging, and tumor trajectory when symptoms change or tumor-directed treatment decisions are being made. [16][20]

Maintain a low threshold to repeat transthoracic echocardiography when symptoms or signs suggest evolving valvular dysfunction or right-sided heart failure. Carcinoid heart disease is a systemic complication of serotonin-secreting disease and is particularly relevant in advanced small-intestinal NET with carcinoid syndrome. [9][16] Valve intervention requires coordinated assessment because active carcinoid syndrome, hepatic dysfunction, and right-heart failure complicate replacement procedures. [24]

For patients undergoing abdominal surgery who are expected to receive long-term somatostatin analog therapy, consider prophylactic cholecystectomy at the time of surgery because prolonged somatostatin analog exposure increases biliary complications such as cholelithiasis and cholecystitis. [19] This is a procedural opportunity decision rather than an indication for stand-alone cholecystectomy in every patient.
- Reassess symptoms, urinary 5-HIAA, and imaging together when therapy appears ineffective; discordant results should prompt distinction between hormone-mediated symptoms and radiographic progression. [16][20]
- Repeat cardiac evaluation when right-heart symptoms, valvular findings, or operative planning emerge. [18][19][24]
- Consider concomitant prophylactic cholecystectomy during abdominal surgery in patients anticipated to receive long-term somatostatin analog therapy. [19]

*Monitoring domains that alter management in carcinoid syndrome. [9][16][19][20][24]*

| Domain | Assessment | Management trigger |
| --- | --- | --- |
| Hormonal activity [16][20] | Symptoms and urinary 5-HIAA. [16][20] | Persistent or worsening biochemical and clinical activity supports escalation of antisecretory or serotonin-directed therapy. [15][20] |
| Tumor burden [16] | Imaging for localization, staging, and reassessment when clinical status changes. [16] | Progressive or liver-dominant disease supports consideration of PRRT, systemic therapy, or liver-directed treatment. [8][12] |
| Cardiac involvement [9][19][24] | Transthoracic echocardiography for valvular dysfunction and heart failure. [19] | Clinically significant valve disease requires multidisciplinary valve and NET planning. [24] |
| Biliary risk during long-term somatostatin analog use [19] | Assess whether abdominal surgery is planned. [19] | Consider prophylactic cholecystectomy during the abdominal operation. [19] |

## References
1. Surgical Management of Left-Sided Carcinoid Heart Disease — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circ.104.suppl_1.i-36
2. Carcinoid Heart Disease | Circulation — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/circulationaha.107.701367
3. Consensus guideline for the management of peritoneal ... — acsjournals.onlinelibrary.wiley.com — https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35871
4. ENDOCRINOLOGY IN THE TIME OF COVID-19: Clinical ... — academic.oup.com — https://academic.oup.com/ejendo/article/183/2/G79/6653752
5. Outcomes, risks and complications of cardiac surgery for ... — academic.oup.com — https://academic.oup.com/ejcts/article/40/1/168/600451
6. Edotreotide - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/edotreotide
7. Carcinoid syndrome and neuroendocrine tumours — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1357303925001896
8. Peptide Receptor Radionuclide Therapy With 177 Lu ... — academic.oup.com — https://academic.oup.com/jcem/article/106/9/e3665/6263447
9. Carcinoid heart disease in patients with advanced small ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2059702924017290
10. Telotristat - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/telotristat
11. European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9539661
12. The North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5642985
13. Gastrointestinal Neuroendocrine Tumors and the Carcinoid Syndrome - Endotext - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK279162
14. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC5678742
15. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4304762
16. Carcinoid Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK448096
17. European Society of Neuroendocrine Tumors (ENETS ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/41941890?fc=None&ff=20260407183352&v=2.19.0.post6+133c1fe
18. Symptom Management for Well-Differentiated ... — ascopubs.org — https://ascopubs.org/doi/10.1200/OP-25-00133
19. Gastrointestinal Neuroendocrine Tumors - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK448101
20. Xermelo 250 mg film-coated tablets — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/product-information/xermelo-epar-product-information_en.pdf
21. Xermelo, INN-telotristat - European Medicines Agency — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/assessment-report/xermelo-epar-public-assessment-report_en.pdf
22. Octreotide | Drug Lookup | Pediatric Care Online — publications.aap.org — https://publications.aap.org/pediatriccare/drug-monograph/18/5747/Octreotide
23. ADULT MALE DEVELOPS CARCINOID CRISIS ON ... — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(23)02514-X/fulltext
24. Improving outcome of valve replacement for carcinoid heart ... — www.jtcvs.org — https://www.jtcvs.org/article/S0022-5223(18)32526-1/pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.